Works in Cancer Immunology, Immunotherapy, 2023, Vol 72, Issue 10

Results: 21

Correction to: Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.

Published in:

2023

By:

Chen, Jiannan;
Hu, Jianhua;
Gu, Lili;
Ji, Feng;
Zhang, Fan;
Zhang, Miaomiao;
Li, Jun;
Chen, Zhengliang;
Jiang, Longwei;
Zhang, Yan;
Shi, Ruifang;
Ma, Lihua;
Jia, Shaochang;
Zhang, Ying;
Zhang, Qi;
Liang, Junqing;
Yao, Shunyu;
Hu, Zhigang;
Guo, Zhigang

Publication type:

Correction Notice

Decoding the genetic links between serum lipidomic profile, amino acid biomarkers, and programmed cell death protein-1/programmed cell death-ligand-1.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3395, doi. 10.1007/s00262-023-03501-8

By:

Li, Wenjie;
Wang, Wei

Publication type:

Article

Successful ex vivo expansion of tumor infiltrating lymphocytes with systemic chemotherapy prior to surgical resection.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3377, doi. 10.1007/s00262-023-03500-9

By:

Balzeau, Julien;
Ravindran, Anindita;
Wang, Xin;
Maisuria, Jinal;
Lucchesi, Anna;
Yao, Hui;
Matsueda, Satoko

Publication type:

Article

Immune checkpoint inhibitor treatment of brain metastasis associated with a less invasive growth pattern, higher T-cell infiltration and raised tumor ADC on diffusion weighted MRI.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3387, doi. 10.1007/s00262-023-03499-z

By:

Zakaria, Rasheed;
Jenkinson, Michael D.;
Radon, Mark;
Das, Kumar;
Poptani, Harish;
Rathi, Nitika;
Rudland, Philip S.

Publication type:

Article

Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3349, doi. 10.1007/s00262-023-03496-2

By:

Maldonado, Maria del Mar;
Schlom, Jeffrey;
Hamilton, Duane H.

Publication type:

Article

Circadian pattern subtyping unveiling distinct immune landscapes in breast cancer patients for better immunotherapy.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3293, doi. 10.1007/s00262-023-03495-3

By:

Xiong, Siqi;
Zhu, Wenqiang;
Wu, Liqing;
Zhou, Tianmin;
Wang, Wu;
Zhang, Ouyang;
Xiong, Xiaoliang;
Liu, Zhuoqi;
Luo, Daya

Publication type:

Article

Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3337, doi. 10.1007/s00262-023-03494-4

By:

Jokimäki, Anna;
Hietala, Henna;
Lemma, Jasmiini;
Karhapää, Hanna;
Rintala, Anna;
Kaikkonen, Jari-Pekka;
Sunela, Kaisa;
Boman, Eva;
Jukkola, Arja;
Tiainen, Satu;
Seppälä, Jan;
Rönkä, Aino;
Hakkarainen, Heikki;
Kärnä, Aarno;
Iivanainen, Sanna;
Koivunen, Jussi;
Auvinen, Päivi;
Hernberg, Micaela;
Kuusisto, Milla;
Selander, Tuomas

Publication type:

Article

Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3363, doi. 10.1007/s00262-023-03493-5

By:

Modestino, Luca;
Cristinziano, Leonardo;
Trocchia, Marialuisa;
Ventrici, Annagioia;
Capone, Mariaelena;
Madonna, Gabriele;
Loffredo, Stefania;
Ferrara, Anne Lise;
Romanelli, Marilena;
Simeone, Ester;
Varricchi, Gilda;
Rossi, Francesca Wanda;
de Paulis, Amato;
Marone, Gianni;
Ascierto, Paolo Antonio;
Galdiero, Maria Rosaria

Publication type:

Article

Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3323, doi. 10.1007/s00262-023-03492-6

By:

de Jonge, P. K. J. D.;
van Hauten, P. M. M.;
Janssen, L. D.;
de Goede, A. L.;
Berrien-Elliott, M. M.;
van der Meer, J. M. R.;
Mousset, C. M.;
Roeven, M. W. H.;
Foster, M.;
Blijlevens, N.;
Hobo, W.;
Fehniger, T. A.;
Jansen, J. H.;
Schaap, N. P. M.;
Dolstra, H.

Publication type:

Article

CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3191, doi. 10.1007/s00262-023-03491-7

By:

Yang, Peiwei;
Yu, Fan;
Yao, Zheng;
Ding, Xu;
Xu, Hanmei;
Zhang, Juan

Publication type:

Article

Chimeric antigen receptor macrophages activated through TLR4 or IFN-γ receptors suppress breast cancer growth by targeting VEGFR2.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3243, doi. 10.1007/s00262-023-03490-8

By:

Duan, Zhaojun;
Li, Zhen;
Wang, Ziyuan;
Chen, Chong;
Luo, Yunping

Publication type:

Article

Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3217, doi. 10.1007/s00262-023-03489-1

By:

Nelli, Fabrizio;
Giannarelli, Diana;
Fabbri, Agnese;
Virtuoso, Antonella;
Giron Berrios, Julio Rodrigo;
Marrucci, Eleonora;
Fiore, Cristina;
Schirripa, Marta;
Signorelli, Carlo;
Chilelli, Mario Giovanni;
Primi, Francesca;
Panichi, Valentina;
Topini, Giuseppe;
Silvestri, Maria Assunta;
Ruggeri, Enzo Maria

Publication type:

Article

SIGLEC10+ macrophages drive gastric cancer progression by suppressing CD8+ T cell function.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3229, doi. 10.1007/s00262-023-03488-2

By:

Guo, Yixian;
Ke, Shouyu;
Xie, Feng;
Chen, Jieqiong;
Liu, Xu;
Wang, Zeyu;
Xu, Danhua;
Shen, Yanying;
Zhao, Gang;
Zhao, Wenyi;
Lu, Hong

Publication type:

Article

Piper nigrum extract suppresses tumor growth and enhances the antitumor immune response in murine models of breast cancer and melanoma.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3279, doi. 10.1007/s00262-023-03487-3

By:

Lasso, Paola;
Rojas, Laura;
Arévalo, Cindy;
Urueña, Claudia;
Murillo, Natalia;
Nossa, Paula;
Sandoval, Tito;
Chitiva, Luis Carlos;
Barreto, Alfonso;
Costa, Geison M.;
Fiorentino, Susana

Publication type:

Article

Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3309, doi. 10.1007/s00262-023-03486-4

By:

Grard, Marion;
Idjellidaine, Mohamed;
Arbabian, Atousa;
Chatelain, Camille;
Berland, Laurine;
Combredet, Chantal;
Dutoit, Soizic;
Deshayes, Sophie;
Dehame, Virginie;
Labarrière, Nathalie;
Fradin, Delphine;
Boisgerault, Nicolas;
Blanquart, Christophe;
Tangy, Frédéric;
Fonteneau, Jean-François

Publication type:

Article

Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3259, doi. 10.1007/s00262-023-03485-5

By:

Huang, Liling;
Lou, Ning;
Xie, Tongji;
Tang, Le;
Han, Xiaohong;
Shi, Yuankai

Publication type:

Article

DLGAP5 promotes gallbladder cancer migration and tumor-associated macrophage M2 polarization by activating cAMP.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3203, doi. 10.1007/s00262-023-03484-6

By:

Huang, Jie;
Zheng, Mengyao;
Li, Yan;
Xu, Dingwei;
Tian, Daguang

Publication type:

Article

Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3175, doi. 10.1007/s00262-023-03482-8

By:

Takei, Jun;
Kamata, Yuko;
Tanaka, Toshihide;
Fukasawa, Nei;
Gomisawa, Kazutaka;
Satake, Mari;
Mori, Ryosuke;
Yamamoto, Yohei;
Suzuki, Tomoya;
Oda, Ayaka;
Murahashi, Mutsunori;
Fukuda, Takahiro;
Shimoda, Masayuki;
Murayama, Yuichi;
Akasaki, Yasuharu

Publication type:

Article

Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3135, doi. 10.1007/s00262-023-03480-w

By:

Veen, Torhild;
Kanani, Arezo;
Lea, Dordi;
Søreide, Kjetil

Publication type:

Article

Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3149, doi. 10.1007/s00262-023-03476-6

By:

Parikh, Anup Y.;
Masi, Robert;
Gasmi, Billel;
Hanada, Ken-ichi;
Parkhurst, Maria;
Gartner, Jared;
Sindiri, Sivasish;
Prickett, Todd;
Robbins, Paul;
Zacharakis, Nikolaos;
Beshiri, Mike;
Kelly, Kathleen;
Rosenberg, Steven A.;
Yang, James C.

Publication type:

Article

Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 10, p. 3163, doi. 10.1007/s00262-023-03475-7

By:

Cheng, Jiali;
Zhao, Yuyan;
Hu, Hui;
Tang, Ling;
Zeng, Yuhao;
Deng, Xinyue;
Ding, Shengnan;
Guo, An-Yuan;
Li, Qing;
Zhu, Xiaojian

Publication type:

Article

Works in Cancer Immunology, Immunotherapy, 2023, Vol 72, Issue 10

Correction to: Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.

Decoding the genetic links between serum lipidomic profile, amino acid biomarkers, and programmed cell death protein-1/programmed cell death-ligand-1.

Successful ex vivo expansion of tumor infiltrating lymphocytes with systemic chemotherapy prior to surgical resection.

Immune checkpoint inhibitor treatment of brain metastasis associated with a less invasive growth pattern, higher T-cell infiltration and raised tumor ADC on diffusion weighted MRI.

Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment.

Circadian pattern subtyping unveiling distinct immune landscapes in breast cancer patients for better immunotherapy.

Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events.

Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps.

Good manufacturing practice production of CD34<sup>+</sup> progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia.

CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer.

Chimeric antigen receptor macrophages activated through TLR4 or IFN-γ receptors suppress breast cancer growth by targeting VEGFR2.

Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.

SIGLEC10<sup>+</sup> macrophages drive gastric cancer progression by suppressing CD8<sup>+</sup> T cell function.

Piper nigrum extract suppresses tumor growth and enhances the antitumor immune response in murine models of breast cancer and melanoma.

Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells.

Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing.

DLGAP5 promotes gallbladder cancer migration and tumor-associated macrophage M2 polarization by activating cAMP.

Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma.

Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer.

Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens.

Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics.